-
We detected your language preference as English. Would you like to switch to the English version for a better experience?
Switch to English
Stay here
Revenue from major segments in the first three quarters included:
Several of Novartis' major products have shown steady growth, such as Entresto (sacubitril/valsartan), Cosentyx (secukinumab), and Kesimpta (ofatumumab). Some products have achieved rapid growth, including Kisqali (ribociclib), Pluvicto (lutetium Lu 177 vipivotide tetraxetan), Leqvio (inclisiran), and Scemblix (asciminib).
Novartis' TOP 20 best-selling drugs in the first three quarters of 2024
In the cardiovascular-renal-metabolic field, Novartis' two revolutionary drugs Entresto (sacubitril valsartan) and Leqvio (Incosilan) contributed revenues of $5.642 billion (+30%) and $531 million (+130%) respectively. Entresto will face a greater threat next year. On the one hand, Novartis expects that generic Entresto will enter the US market in mid-2025. On the other hand, Entresto has entered the first round of US health insurance negotiation price reduction list, with a price reduction of 53% (starting in 2026).
Although Leqvio (Inxilma) is also under competitive pressure from PCSK9 monoclonal antibodies such as evolocumab and tolcizumab, it has a good growth momentum. Novartis is still continuing to expand the application boundaries of Leqvio and has planned to submit a marketing application for the drug to reduce LDL-C levels in patients with low or medium ASCVD risk.
Notably, in the third quarter, Novartis received approval for Fabhalta (ipkacopan) for IgA nephropathy, marking it as the first complement-targeting drug approved for the treatment of this condition, offering a new therapeutic option for these patients. Additionally, following the successful Phase III APPEAR-C3G study, Novartis has submitted applications in both the U.S. and China to expand Fabhalta's indication for the treatment of C3 glomerulopathy.
In the immunology field, Novartis’ flagship product Cosentyx (secukinumab) also faces competitive pressure from multiple products. However, it gained approval in 2023 for the treatment of hidradenitis suppurativa (HS), making Cosentyx the first new therapy in nearly a decade for HS, providing new momentum for its sales growth. Cosentyx's patent will expire in 2025, after which it will face competition from biosimilar products. Currently, several pharmaceutical companies (including Bio-Thera, CSPC, and Mabwell) have secukinumab biosimilars in Phase III trials.
In the neuroscience field, Kesimpta (ofatumumab) remains the only self-injectable anti-CD20 monoclonal antibody, giving it a distinct advantage in the multiple sclerosis (MS) market and supporting its steady growth. A strong competitor from Roche, Ocrevus (ocrelizumab), introduced a subcutaneous formulation this year with the benefit of a lower injection frequency (twice a year versus once a month). However, Ocrevus still requires administration under medical supervision. Kesimpta's patent expired in 2023, but no biosimilar is currently in clinical development.
In the oncology field, the CDK4/6 inhibitor Kisqali (ribociclib) has made the largest contribution to revenue, with sales reaching $2.131 billion (+48%), accounting for 20% of oncology revenue. In Q3, Kisqali gained two new indications in the U.S.: (1) in combination with an aromatase inhibitor as initial endocrine therapy for adult patients with HR+/HER2- advanced or metastatic breast cancer, or in combination with fulvestrant for patients whose disease has progressed following endocrine therapy; and (2) in combination with an aromatase inhibitor as adjuvant therapy for HR+/HER2- early breast cancer (EBC) patients with high recurrence risk in Stage II and III, including lymph node-negative (N0) patients. This expanded coverage to earlier-stage HR+/HER2- breast cancer patients has created new growth opportunities for Kisqali.
Another major oncology product from Novartis, Pluvicto, also delivered impressive results, with revenue reaching $1.041 billion in the first three quarters (+47%). Currently, Pluvicto is approved for third-line treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). According to the Novartis financial report, the company has submitted an application for Pluvicto's use in second-line treatment for PSMA-positive mCRPC. If this indication is approved, Pluvicto's annual sales are expected to reach new highs.
In light of its current performance, Novartis has raised its 2024 full-year growth forecast from high single digits to low double digits.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
